Xylazine hydrochloride-induced hyperglycemia and hypoinsulinemia in thoroughbred horses.

The research investigates the impact of intravenously administered xylazine on glucose and insulin levels in thoroughbred horses, noting a rise in glucose levels and a decrease in insulin, highlighting the need for further investigations.

Objective of the Research

• The primary aim of this research was to study the effect of intravenous xylazine on the plasma glucose concentration and insulin level in thoroughbred horses. Xylazine is an α2-adrenoceptor agonist commonly used for sedation, analgesics, and muscle relaxation in both large and small animals.

Methodology of Research

• The researchers administered Xylazine hydrochloride (1.1 mg/kg) intravenously to six thoroughbred horses (five mares and one stallion) that were the subjects of the study.
• The plasma glucose concentration and insulin levels of the horses were then monitored for changes over a certain period.

Findings of the Research

• Within 45 minutes of administrating xylazine, the concentration of plasma glucose in the horses significantly increased to 168% of the control level. However, this concentration went back down to about 112% of the control level at 180 minutes post-administration.
• Conversely, the insulin concentration in the horses decreased to 31% of the control level at 15 minutes after administration of xylazine. It then increased, to find its highest concentration at 150 minutes post-administration.

Implication of the Findings

• These findings suggest that the administration of xylazine could result in hyperglycemia (high blood sugar levels) and hypoinsulinemia (low levels of insulin) in thoroughbred horses. However, the exact mechanism of how this occurs remains unclear.
• The researchers concluded that these changes are significant and warrant further investigation to fully understand the relationship between xylazine and its effects on glucose and insulin levels in horses.